UBS Group
RVNC

UBS Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

UBS Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,483,040
Closed -$4.51M – 11010
2024
Q4 		$4.51M Buy
1,483,040
+850,487
+134% +$3.7M ﹤0.01% 3947
2024
Q3 		$3.28M Buy
632,553
+581,780
+1,146% +$2.89M ﹤0.01% 3493
2024
Q2 		$130K Sell
50,773
-139,419
-73% -$476K ﹤0.01% 5979
2024
Q1 		$936K Sell
190,192
-3,961
-2% -$23.4K ﹤0.01% 4657
2023
Q4 		$1.71M Buy
194,153
+76,108
+64% +$624K ﹤0.01% 3983
2023
Q3 		$1.35M Sell
118,045
-11,980
-9% -$230K ﹤0.01% 3824
2023
Q2 		$3.29M Sell
130,025
-1,264
-1% -$39.4K ﹤0.01% 3008
2023
Q1 		$4.23M Buy
131,289
+58,464
+80% +$1.82M ﹤0.01% 2675
2022
Q4 		$1.34M Sell
72,825
-9,937
-12% -$227K ﹤0.01% 3786
2022
Q3 		$2.23M Sell
82,762
-4,147
-5% -$84.1K ﹤0.01% 3060
2022
Q2 		$1.2M Sell
86,909
-2,361
-3% -$36.3K ﹤0.01% 3584
2022
Q1 		$1.74M Buy
89,270
+4,615
+5% +$70K ﹤0.01% 3562
2021
Q4 		$1.38M Buy
84,655
+23,374
+38% +$390K ﹤0.01% 4092
2021
Q3 		$1.71M Buy
61,281
+8,099
+15% +$231K ﹤0.01% 3716
2021
Q2 		$1.58M Sell
53,182
-952
-2% -$27.5K ﹤0.01% 3792
2021
Q1 		$1.51M Buy
54,134
+6,140
+13% +$170K ﹤0.01% 3843
2020
Q4 		$1.36M Sell
47,994
-511
-1% -$13.2K ﹤0.01% 3756
2020
Q3 		$1.22M Sell
48,505
-4,648
-9% -$122K ﹤0.01% 3499
2020
Q2 		$1.3M Buy
53,153
+12,427
+31% +$245K ﹤0.01% 3284
2020
Q1 		$603K Buy
40,726
+11,476
+39% +$237K ﹤0.01% 3793
2019
Q4 		$474K Buy
29,250
+27,850
+1,989% +$432K ﹤0.01% 4885
2019
Q3 		$18K Hold
1,400
– – ﹤0.01% 6807
2019
Q2 		$18K Buy
1,400
+184
+15% +$2.32K ﹤0.01% 6696
2019
Q1 		$19K Buy
1,216
+768
+171% +$13.3K ﹤0.01% 6361
2018
Q4 		$9K Sell
448
-1,617
-78% -$35.6K ﹤0.01% 7298
2018
Q3 		$52K Sell
2,065
-1,383
-40% -$37.6K ﹤0.01% 6134
2018
Q2 		$95K Buy
3,448
+854
+33% +$25.7K ﹤0.01% 5482
2018
Q1 		$80K Buy
2,594
+214
+9% +$6.88K ﹤0.01% 5379
2017
Q4 		$85K Buy
2,380
+46
+2% +$1.32K ﹤0.01% 5474
2017
Q3 		$64K Buy
2,334
+1,823
+357% +$44.2K ﹤0.01% 5624
2017
Q2 		$13K Buy
511
+500
+4,545% +$11.1K ﹤0.01% 6610
2017
Q1 		$0 Sell
11
-1,041
-99% -$21.4K ﹤0.01% 8057
2016
Q4 		$22K Sell
1,052
-844
-45% -$14.1K ﹤0.01% 6463
2016
Q3 		$31K Buy
1,896
+1,385
+271% +$20.1K ﹤0.01% 5903
2016
Q2 		$7K Hold
511
– – ﹤0.01% 6995
2016
Q1 		$9K Sell
511
-1,378
-73% -$28K ﹤0.01% 6733
2015
Q4 		$64K Buy
1,889
+1,389
+278% +$48.2K ﹤0.01% 5602
2015
Q3 		$15K Hold
500
– – ﹤0.01% 6975
2015
Q2 		$16K Sell
500
-157
-24% -$4.04K ﹤0.01% 7089
2015
Q1 		$13K Sell
657
-648
-50% -$11.2K ﹤0.01% 7444
2014
Q4 		$22K Buy
+1,305
New +$22.8K ﹤0.01% 7535

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's RVNC Position: Q1 2025 in Review

UBS Group sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,483,040 shares — an estimated $4.51M sold.

UBS Group first reported a position in RVNC in Q4 2014 and held it in 41 quarters. The position peaked at $4.51M in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • UBS Group reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • UBS Group sold 1,483,040 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $4.51M.
  • UBS Group first reported a position in Revance Therapeutics, Inc. in Q4 2014 and held it in 41 quarters.
  • UBS Group's Revance Therapeutics, Inc. position peaked at $4.51M in Q4 2024.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on UBS Group's 13F filing for Q1 2025, filed 13 May 2025.